IL143402A0 - Fused 1,2,4-thiadiazine derivatives, their preparation and use - Google Patents
Fused 1,2,4-thiadiazine derivatives, their preparation and useInfo
- Publication number
- IL143402A0 IL143402A0 IL14340299A IL14340299A IL143402A0 IL 143402 A0 IL143402 A0 IL 143402A0 IL 14340299 A IL14340299 A IL 14340299A IL 14340299 A IL14340299 A IL 14340299A IL 143402 A0 IL143402 A0 IL 143402A0
- Authority
- IL
- Israel
- Prior art keywords
- fused
- preparation
- thiadiazine derivatives
- compounds
- thiadiazine
- Prior art date
Links
- 150000008337 1,2,4-thiadiazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 210000005095 gastrointestinal system Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801693 | 1998-12-18 | ||
| DKPA199900018 | 1999-01-11 | ||
| PCT/DK1999/000702 WO2000037474A1 (en) | 1998-12-18 | 1999-12-15 | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143402A0 true IL143402A0 (en) | 2002-04-21 |
Family
ID=26063128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14340299A IL143402A0 (en) | 1998-12-18 | 1999-12-15 | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1338600A1 (pt) |
| JP (1) | JP2002533347A (pt) |
| KR (1) | KR20010086126A (pt) |
| CN (1) | CN1137125C (pt) |
| AT (1) | ATE242254T1 (pt) |
| AU (1) | AU1649900A (pt) |
| BR (1) | BR9916279A (pt) |
| CA (1) | CA2353907A1 (pt) |
| CZ (1) | CZ20011831A3 (pt) |
| DE (1) | DE69908648T2 (pt) |
| DK (1) | DK1140945T3 (pt) |
| ES (1) | ES2200575T3 (pt) |
| HU (1) | HUP0104646A3 (pt) |
| IL (1) | IL143402A0 (pt) |
| NO (1) | NO20012966D0 (pt) |
| PL (1) | PL348237A1 (pt) |
| PT (1) | PT1140945E (pt) |
| WO (1) | WO2000037474A1 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000222A1 (en) * | 2000-06-26 | 2002-01-03 | Novo Nordisk A/S | Use of potassium channel agonists for the treatment of cancer |
| WO2002000665A1 (en) * | 2000-06-26 | 2002-01-03 | Novo Nordisk A/S | Use of potassium channel openers for the treatment of insulitis |
| WO2002050085A1 (en) * | 2000-12-21 | 2002-06-27 | Novo Nordisk A/S | A new process for preparing fused 1,2,4-thiadiazine derivatives |
| EP1386908B1 (en) | 2001-01-19 | 2010-03-03 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. | Amine derivative with potassium channel regulatory function, its preparation and use |
| JP4563675B2 (ja) | 2001-10-12 | 2010-10-13 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 置換ピペリジン類、およびヒスタミンh3受容体関連疾患の治療のためのその使用 |
| WO2003045955A1 (en) * | 2001-11-30 | 2003-06-05 | Novo Nordisk A/S | Use of selective potassium channel openers |
| AU2002342600A1 (en) * | 2001-11-30 | 2003-06-10 | Novo Nordisk A/S | Use of selective potassium channel openers |
| MXPA04006048A (es) | 2001-12-21 | 2004-09-27 | Novo Nordisk As | Derivados de amida como activadores de glucocinasa. |
| AU2003232171A1 (en) * | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a beta cell resting compound |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| WO2004005299A1 (en) * | 2002-07-04 | 2004-01-15 | Novo Nordisk A/S | Polymorphic forms of a 4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivative |
| WO2005030797A2 (en) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Melanocortin receptor agonists |
| DE602004031455D1 (de) | 2003-12-09 | 2011-03-31 | Novo Nordisk As | Regulierung der nahrungspräferenz mit glp-1-agonisten |
| PL1723128T3 (pl) | 2004-01-06 | 2013-04-30 | Novo Nordisk As | Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy |
| US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
| JP4874989B2 (ja) | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー/エス | 可溶性で安定なインスリン含有調合物 |
| US8148412B2 (en) | 2004-12-03 | 2012-04-03 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
| JP5410020B2 (ja) | 2005-02-02 | 2014-02-05 | ノヴォ ノルディスク アー/エス | インスリン誘導体 |
| ES2428510T3 (es) | 2005-02-02 | 2013-11-08 | Novo Nordisk A/S | Derivados de insulina |
| EP1879567A1 (en) | 2005-04-28 | 2008-01-23 | Pfizer Limited | Amino acid derivatives |
| US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
| JP4960355B2 (ja) | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー/エス | ウレア型グルコキナーゼ活性化剤 |
| WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
| SI1951658T1 (sl) | 2005-11-17 | 2012-11-30 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava interapevtska uporaba |
| ES2388681T3 (es) | 2006-03-28 | 2012-10-17 | High Point Pharmaceuticals, Llc | Benzotiazoles con actividad de los receptores de histamina H3 |
| CN100500672C (zh) * | 2006-04-20 | 2009-06-17 | 山东大学 | N1,N3-二取代噻吩并[3,2-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物与应用 |
| AU2007267197B2 (en) | 2006-05-29 | 2011-12-01 | High Point Pharmaceuticals, Llc | 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
| US8022066B2 (en) | 2006-11-15 | 2011-09-20 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| US8318778B2 (en) | 2007-01-11 | 2012-11-27 | Novo Nordisk A/S | Urea glucokinase activators |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| EP2539364A1 (en) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Peptides for treatment of obesity |
| BR112012024379A2 (pt) | 2010-03-26 | 2017-01-10 | Novo Nordisk As | "peptídeos glucagon, seu uso, bem como composição farmacêutica" |
| BR112013024076A2 (pt) | 2011-03-28 | 2016-12-06 | Novo Nordisk As | análogos de glucagon |
| CN104093735B (zh) | 2011-09-23 | 2018-07-06 | 诺沃—诺迪斯克有限公司 | 新的胰高血糖素类似物 |
| WO2014093696A2 (en) | 2012-12-12 | 2014-06-19 | Massachusetts Institute Of Technology | Insulin derivatives for diabetes treatment |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
| EP3201204B1 (en) | 2014-10-03 | 2021-02-24 | Merck Sharp & Dohme Corp. | C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP3596107A1 (en) | 2017-03-15 | 2020-01-22 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU727775B2 (en) * | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL133604A0 (en) * | 1997-07-16 | 2001-04-30 | Novo Nordisk As | Fused 1, 2, 4-thiadiazine derivatives, their preparation and use |
-
1999
- 1999-12-15 HU HU0104646A patent/HUP0104646A3/hu unknown
- 1999-12-15 PT PT99959255T patent/PT1140945E/pt unknown
- 1999-12-15 DK DK99959255T patent/DK1140945T3/da active
- 1999-12-15 EP EP03006331A patent/EP1338600A1/en not_active Withdrawn
- 1999-12-15 JP JP2000589544A patent/JP2002533347A/ja active Pending
- 1999-12-15 CZ CZ20011831A patent/CZ20011831A3/cs unknown
- 1999-12-15 KR KR1020017007713A patent/KR20010086126A/ko not_active Withdrawn
- 1999-12-15 DE DE69908648T patent/DE69908648T2/de not_active Expired - Fee Related
- 1999-12-15 PL PL99348237A patent/PL348237A1/xx not_active Application Discontinuation
- 1999-12-15 AT AT99959255T patent/ATE242254T1/de active
- 1999-12-15 CN CNB998144894A patent/CN1137125C/zh not_active Expired - Fee Related
- 1999-12-15 EP EP99959255A patent/EP1140945B1/en not_active Expired - Lifetime
- 1999-12-15 AU AU16499/00A patent/AU1649900A/en not_active Abandoned
- 1999-12-15 CA CA002353907A patent/CA2353907A1/en not_active Abandoned
- 1999-12-15 BR BR9916279-2A patent/BR9916279A/pt not_active IP Right Cessation
- 1999-12-15 IL IL14340299A patent/IL143402A0/xx unknown
- 1999-12-15 WO PCT/DK1999/000702 patent/WO2000037474A1/en not_active Ceased
- 1999-12-15 ES ES99959255T patent/ES2200575T3/es not_active Expired - Lifetime
-
2001
- 2001-06-15 NO NO20012966A patent/NO20012966D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1137125C (zh) | 2004-02-04 |
| ATE242254T1 (de) | 2003-06-15 |
| PT1140945E (pt) | 2003-10-31 |
| BR9916279A (pt) | 2001-10-16 |
| ES2200575T3 (es) | 2004-03-01 |
| WO2000037474A1 (en) | 2000-06-29 |
| DK1140945T3 (da) | 2003-09-15 |
| CA2353907A1 (en) | 2000-06-29 |
| EP1140945A1 (en) | 2001-10-10 |
| PL348237A1 (en) | 2002-05-20 |
| DE69908648T2 (de) | 2004-05-13 |
| AU1649900A (en) | 2000-07-12 |
| HUP0104646A3 (en) | 2004-05-28 |
| HUP0104646A2 (hu) | 2002-04-29 |
| JP2002533347A (ja) | 2002-10-08 |
| NO20012966L (no) | 2001-06-15 |
| CN1330655A (zh) | 2002-01-09 |
| NO20012966D0 (no) | 2001-06-15 |
| CZ20011831A3 (cs) | 2001-10-17 |
| EP1338600A1 (en) | 2003-08-27 |
| KR20010086126A (ko) | 2001-09-07 |
| EP1140945B1 (en) | 2003-06-04 |
| DE69908648D1 (de) | 2003-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL348237A1 (en) | Fused 1,2,4-thiadiazine derivatives, their preparation and use | |
| TWI224595B (en) | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | |
| CA2272705A1 (en) | Fused bicyclic pyrimidine derivatives | |
| WO2000035919A3 (en) | Quinoline derivatives | |
| HK1038744A1 (zh) | 用於治療炎性疾病的化合物 | |
| WO2002041889A3 (en) | Indolsulfonyl compounds useful in the treatment of cns disorders | |
| HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
| PL330815A1 (en) | Derivatives of 1,2,4-benzothiadiasine, their production and application | |
| HUP0200284A3 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| CA2094702A1 (en) | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents | |
| ZA983851B (en) | Substituted 3,3-diamino-2-propenenitriles their preparation and use | |
| BG104983A (en) | Aryl fused azapolycyclic compounds | |
| HUP0301080A3 (en) | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives, process for their preparation and pharmaceutical compositions containing them | |
| CA2264005A1 (en) | Piperazino derivatives as neurokinin antagonists | |
| HUP0100934A3 (en) | Use of fused pyridine derivatives for production pharmaceutical compositions for the treatment of depression, anxiety or psychopathy | |
| IL141325A0 (en) | Tan-1057 derivatives | |
| HUP0401325A3 (en) | Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds | |
| YU19302A (sh) | 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena | |
| HUP0400773A3 (en) | 7-(4-tert-butylyclohexyl)-5-ethyl-3h-imidazo[5,1-f][1,2,4]triazin-4-on derivatives, their use pharmaceutical compositions containing them and process for the preparation of the compounds | |
| WO2004048318A8 (en) | Improved process for the preparation of 1,3-substituted indenes | |
| HUP9902737A3 (en) | The use of aryl-cyclohexylamine derivatives for preparing pharmaceutical compositions suitable for treatment of cns disorders | |
| HUP0004916A3 (en) | Process for the preparation of 1,2,3,4-tetrahydroisoquinoline-2,3-dicarboxylic acid anhydride and (s)-n-terc-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide by using thereof | |
| EP0276805A3 (en) | Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds | |
| DE50006244D1 (en) | Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine |